

Radius Health Inc

COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 01-Mar-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 10

[Return to Table of Contents](#)

Radius Health Inc

COMPANY OVERVIEW

Company Name	Radius Health Inc
Parent Company Name	Radius Health Inc
Website	http://www.radiuspharm.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	2
Number of Patents as Owner	13
Number of Patents as Third Party	1
Number of Deals	7
Key Indications	Postmenopausal osteoporosis, Osteoporosis, Sarcopenia, Hot flashes, Multiple sclerosis, Breast tumor, Depression, Irritable bowel syndrome, Non-insulin dependent diabetes, Prostate tumor
Key Target-based Actions	Androgen receptor modulator, Parathyroid hormone receptor modulator, Parathyroid hormone receptor agonist, Estrogen receptor antagonist, Estrogen receptor beta modulator, Estrogen receptor modulator, Parathyroid hormone related protein modulator
Key Technologies	Peptide, Patch formulation, Transdermal formulation, Absorption enhancer transdermal, Biological therapeutic, Oral formulation, Small molecule therapeutic, Drug screening, Capsule formulation, Drug coating, Drug combination, Injectable formulation, Tablet formulation

COMPANY PROFILE

SUMMARY

Radius Health Inc (formerly Nuvios) is a US-based, private biotechnology company that aims to discover and develop new agents for treating and preventing metabolic bone diseases, symptoms of menopause and reproductive disorders associated with inflammation.

LICENSING AGREEMENTS

In May 2004, Nuvios entered into a collaboration with Evotec OAI for the screening of small-molecule compounds for the potential treatment and prevention of osteoporosis. Evotec would apply its ultra high-throughput as well as other technologies for the identification of active compounds to Nuvios's assays for profiling the effects of compounds on osteoclast and osteoblast growth and differentiation. The objective of the partnership was to discover novel activators of bone anabolic activity.

FINANCIAL

In April 2013, the company raised \$43 million from an equity financing.

In February 2012, Radius filed a registration statement with the securities and exchange commission relating to a proposed public offering of its common stock. At that time, the number of shares to be offered and the price range for the proposed offering were not yet determined.

In May 2011, the company planned to raise \$91 million from a third financing round, including a total of \$66 million in equity financing and a commitment from GE Capital, Healthcare Financial Services and Oxford Finance for a \$25 million term loan facility. At that time, an initial close gave the company gross proceeds of \$22 million in equity and \$6.25 million in debt, and \$1.4 million of preferred stock was issued to Ipsen in lieu of a cash milestone payment. In November 2011, Radius closed a second tranche of the financing round. The \$27.65 million second tranche included \$21.4 million in equity financing and \$6.25 million in debt; gross proceeds received at that time totalled \$57.3 million. In December 2011, Radius closed a third and final equity tranche of the financing round. The third tranche included \$21.4 million in equity financing; gross proceeds received at that time totalled \$78.7 million. The company had an additional \$12.5 million of debt available to be drawn until May 2012.

[Return to Table of Contents](#)



In November 2008, the company raised \$15 million from an institutional financing round.

In September 2007, Radius reported that the MPM Bio IV NVS Strategic Fund LP had purchased \$10 million of series C preferred Radius stock.

In April 2007, the company raised \$57.5 million in private financing.

EARLY R&D/TECHNOLOGY UPDATES/IP NEWS


Nuvios holds patents covering novel small-molecules known as activators of non-genotropic estrogen-like signaling (ANGELS), a potential new class of anabolic osteoporosis therapy.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Endocrine disease	3	2	5
Degeneration	3	2	5
Musculoskeletal disease	3	2	5
Gynecology and obstetrics	0	2	2
Growth disorder	1	1	2
Cardiovascular disease	1	0	1
Metabolic disorder	0	1	1
Inflammatory disease	0	1	1
Genitourinary disease	0	1	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	2
Discovery	1
Discontinued	1
No Development Reported	1

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Screening/Evaluation	0	0	1	0	1
Drug - Development/Commercialization License	1	1	2	1	4
Drug - Development Services	0	0	1	0	1
Technology - Delivery/Formulation	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Endocrine disease	1	4
Degeneration	1	4
Musculoskeletal disease	1	4
Cardiovascular disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	1	2
Phase 2	0	3
Phase 1	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

[Return to Table of Contents](#)



Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	7	0	7
Endocrine disease	12	1	13
Gastrointestinal disease	6	0	6
Genitourinary disease	5	0	5
Growth disorder	2	0	2
Hematological disease	4	1	5
Degeneration	9	1	10
Andrology	3	0	3
Immune disorder	5	0	5
Psychiatric disorder	4	0	4
Musculoskeletal disease	11	1	12
Neoplasm	5	0	5
Metabolic disorder	6	1	7
Neurological disease	6	0	6
Nutritional disorder	3	0	3
Prophylaxis	1	0	1
Infectious disease	1	0	1
Injury	4	1	5
Inflammatory disease	3	1	4
Gynecology and obstetrics	4	0	4
Surgical procedure	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

abaloparatide SC

Drug Name	abaloparatide SC
Key Synonyms	
Originator Company	Ipsen
Active Companies	Radius Health Inc, Teijin Ltd
Inactive Companies	Ipsen
Highest Status	Phase 3 Clinical
Active Indications	Postmenopausal osteoporosis
Target-based Actions	Parathyroid hormone receptor modulator
Other Actions	Bone modulator
Technologies	Subcutaneous formulation, Biological therapeutic, Peptide
Last Change Date	13-Jan-2014

RAD-1901

Drug Name	RAD-1901
Key Synonyms	
Originator Company	Eisai Co Ltd
Active Companies	Radius Health Inc
Inactive Companies	Eisai Co Ltd
Highest Status	Phase 2 Clinical
Active Indications	Hot flashes
Target-based Actions	Estrogen receptor modulator
Other Actions	Vasoconstrictor, Anticancer
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	29-Sep-2012

[Return to Table of Contents](#)

abaloparatide TD

Drug Name	abaloparatide TD
Key Synonyms	
Originator Company	Radius Health Inc
Active Companies	Radius Health Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Postmenopausal osteoporosis
Target-based Actions	Parathyroid hormone receptor modulator
Other Actions	Bone modulator
Technologies	Transdermal formulation, Patch formulation, Absorption enhancer transdermal, Biological therapeutic, Peptide
Last Change Date	10-Jan-2014

RAD-140

Drug Name	RAD-140
Key Synonyms	
Originator Company	Radius Health Inc
Active Companies	Radius Health Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Osteoporosis, Sarcopenia
Target-based Actions	Androgen receptor modulator
Other Actions	Musculoskeletal system modulator, Bone resorption inhibitor, Neuroprotectant, Non-steroid hormone receptor modulator
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	24-Jul-2013

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

